Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
VERV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.72 per share a year ago.
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
